当前位置：药药医药网 / 数据中心 /药物再评价
名称： 名称(英)：
 药物再评价19557个记录
药物再评价
id
名称
名称(英)
61
达比加群、利伐沙班和华法林预防中国房颤患者脑卒中的成本效果分析
Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
62
载有 CD44v6-O-MWNTS 的吉西他滨和 CXCR4 siRNA 提高了卵巢癌的抗肿瘤效果
CD44v6-O-MWNTS-Loaded Gemcitabine and CXCR4 siRNA Improves the Anti-tumor Effectiveness of Ovarian Cancer
63
天然抗氧化剂2,4,4'-三羟基查耳酮对葵花籽油贮藏氧化的有效性
Effectiveness of the Natural Antioxidant 2,4,4'-Trihydroxychalcone on the Oxidation of Sunflower Oil during Storage
64
美国住院患者 COVID-19 治疗的成本效益框架
A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States
65
成人抑郁症的治疗方式和治疗效果
Treatment Modalities and Perceived Effectiveness of Treatment Among Adults With Depression
66
基于 10 年心血管疾病风险的第一阶段高血压药物治疗的成本效益：马尔可夫模型研究
Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study
67
疟疾的最佳控制：结合媒介干预和药物治疗
Optimal control of malaria: combining vector interventions and drug therapies
68
两种根除幽门螺杆菌常规治疗方法的成本效益分析：波斯队列研究
Cost-effectiveness analysis of two routine therapeutic methods for Helicobacter pylori eradication: a Persian cohort-based study
69
奥匹卡朋和恩他卡朋在减少接受左旋多巴/卡比多巴治疗的帕金森病患者关闭时间方面的成本效益
Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa
70
呋喹替尼与瑞戈非尼作为中国转移性结直肠癌三线治疗的成本效益分析
Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China
71
阿瑞匹坦预防化疗引起的恶心和呕吐的成本效益：已发表文章的系统评价
Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
72
偏头痛患者使用疼痛自我管理策略的频率和感知效果
The Frequency and Perceived Effectiveness of Pain Self-Management Strategies Used by Individuals With Migraine
73
转移性结直肠癌患者 TAS-102 加贝伐单抗与 TAS-102 单药治疗的成本效益
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
74
CYP2C19基因分型指导急性轻度卒中和高危短暂性脑缺血发作抗血小板治疗的成本效益
Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack
75
DIGREM：一个基于网络的集成平台，用于检测有效的多药组合
DIGREM: an integrated web-based platform for detecting effective multi-drug combinations
76
FDA 是否让女性失望？
Is the FDA Failing Women?
77
趋磁 细菌和磁小体作为智能药物输送系统：抗癌战场的新武器？
Magnetotactic Bacteria and Magnetosomes as Smart Drug Delivery Systems: A New Weapon on the Battlefield with Cancer?
78
凝血酶原复合物浓缩物治疗出血的有效性：系统评价和荟萃分析
Effectiveness of prothrombin complex concentrate for the treatment of bleeding: A systematic review and meta-analysis
79
预测室内滞留喷洒减轻登革热负担的效果
Forecasting the effectiveness of indoor residual spraying for reducing dengue burden
80
基于真实世界数据的痛风依从性增强干预的成本效益
Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data

最新招商产品更多>>

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：国家药品监督管理局| 国家中医药管理局| SDA药品评审中心| 化妆品招商网资讯| 卫生部| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网医药代理医药代理商群２：药药网医药代理2医药代理商群３：药药网医药代理3